CY1120854T1 - Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι - Google Patents
Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοιInfo
- Publication number
- CY1120854T1 CY1120854T1 CY181100923T CY181100923T CY1120854T1 CY 1120854 T1 CY1120854 T1 CY 1120854T1 CY 181100923 T CY181100923 T CY 181100923T CY 181100923 T CY181100923 T CY 181100923T CY 1120854 T1 CY1120854 T1 CY 1120854T1
- Authority
- CY
- Cyprus
- Prior art keywords
- related methods
- lipopeptide compositions
- daptomycin
- compositions
- lipopeptide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010028921 Lipopeptides Proteins 0.000 title 1
- 108010013198 Daptomycin Proteins 0.000 abstract 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 2
- 229960005484 daptomycin Drugs 0.000 abstract 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα αποκάλυψη παρέχει νέες φαρμακοτεχνικές μορφές σκόνης δαπτομυκίνης, οι οποίες έχουν βελτιωμένη χημική σταθερότητα και ταχύτερους χρόνους επανασύστασης όταν βρίσκονται σε στερεά κατάσταση. Ορισμένα παραδείγματα των συνθέσεων περιλαμβάνουν δαπτομυκίνη και σακχαρόζη.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26378409P | 2009-11-23 | 2009-11-23 | |
PCT/US2010/057910 WO2011063419A2 (en) | 2009-11-23 | 2010-11-23 | Lipopeptide compositions and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120854T1 true CY1120854T1 (el) | 2019-12-11 |
Family
ID=44060422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181100923T CY1120854T1 (el) | 2009-11-23 | 2018-09-04 | Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι |
Country Status (33)
Country | Link |
---|---|
US (3) | US8835382B2 (el) |
EP (2) | EP2504353B2 (el) |
JP (3) | JP6041673B2 (el) |
CN (3) | CN108785654A (el) |
AR (2) | AR079127A1 (el) |
AU (1) | AU2010321531C1 (el) |
BR (1) | BR112012012406B1 (el) |
CA (1) | CA2781666C (el) |
CL (2) | CL2012001336A1 (el) |
CO (1) | CO6541585A2 (el) |
CR (1) | CR20120271A (el) |
CY (1) | CY1120854T1 (el) |
DK (1) | DK2504353T4 (el) |
DO (1) | DOP2012000140A (el) |
EC (1) | ECSP12011939A (el) |
ES (1) | ES2686331T5 (el) |
FI (1) | FI2504353T4 (el) |
HR (1) | HRP20181380T4 (el) |
HU (1) | HUE039967T2 (el) |
IL (1) | IL219891B (el) |
LT (1) | LT2504353T (el) |
MX (1) | MX2012005993A (el) |
NZ (1) | NZ600118A (el) |
PE (2) | PE20121517A1 (el) |
PL (1) | PL2504353T5 (el) |
PT (1) | PT2504353T (el) |
RS (1) | RS57566B2 (el) |
RU (1) | RU2607526C2 (el) |
SG (1) | SG10201407724YA (el) |
SI (1) | SI2504353T2 (el) |
TR (1) | TR201812823T4 (el) |
TW (2) | TWI606838B (el) |
WO (1) | WO2011063419A2 (el) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
US8835382B2 (en) | 2009-11-23 | 2014-09-16 | Cubist Pharmaceuticals, Inc. | Lipopeptide compositions and related methods |
CN103429228B (zh) | 2011-01-05 | 2016-10-26 | 赫士睿股份有限公司 | 万古霉素的喷雾干燥 |
BR112013030369A2 (pt) * | 2011-05-26 | 2016-12-13 | Cubist Pharm Inc | composições de cb-183,315 e métodos relacionados |
MX2014008390A (es) * | 2012-01-12 | 2014-09-22 | Celgene Corp | Formulaciones de romidepsina y sus usos. |
PT2887953T (pt) * | 2012-08-23 | 2018-01-10 | Mylan Laboratories Ltd | Formulação injetável de daptomicina melhorada |
EP4066849A1 (en) | 2012-09-11 | 2022-10-05 | Hospira Australia Pty Ltd | Daptomycin formulations and uses thereof |
CN104027791B (zh) * | 2013-03-06 | 2016-08-10 | 浙江海正药业股份有限公司 | 药物组合物 |
CN104511011A (zh) * | 2013-09-29 | 2015-04-15 | 山东新时代药业有限公司 | 一种达托霉素无菌粉末及其制备方法 |
US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
US10933019B2 (en) | 2016-10-21 | 2021-03-02 | Xellia Pharmaceuticals Aps | Liquid formulations of daptomycin |
CN111093625A (zh) * | 2017-08-31 | 2020-05-01 | 埃克斯利亚制药有限公司 | 达托霉素制剂 |
CN110339341A (zh) * | 2018-04-03 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 一种达托霉素或其盐的组合物 |
CN110548130A (zh) * | 2018-06-04 | 2019-12-10 | 浙江医药股份有限公司新昌制药厂 | 含达托霉素的喷雾干粉及其工业化制备方法 |
US11058745B1 (en) | 2018-10-04 | 2021-07-13 | Good Health, Llc | Stable liquid pharmaceutical compositions of daptomycin |
CN111840511A (zh) * | 2019-04-30 | 2020-10-30 | 江苏恒瑞医药股份有限公司 | 一种含有精氨酸的达托霉素或其盐的组合物 |
CN114828873A (zh) * | 2019-12-26 | 2022-07-29 | 尼普洛株式会社 | 含有达托霉素的稳定的冷冻干燥制剂 |
EP4110303A1 (en) | 2020-02-28 | 2023-01-04 | Xellia Pharmaceuticals ApS | Daptomycin formulation |
CA3170514A1 (en) | 2020-03-12 | 2021-09-16 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
US11362190B2 (en) | 2020-05-22 | 2022-06-14 | Raytheon Company | Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers |
KR102218688B1 (ko) * | 2020-06-25 | 2021-02-22 | 주식회사 클린텍 | 무선제어기능을 구비한 고압세척기 |
RU2770481C1 (ru) * | 2021-06-25 | 2022-04-18 | федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) | Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331594A (en) | 1978-10-16 | 1982-05-25 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
EP0014815A3 (de) | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen |
US4432487A (en) | 1982-01-18 | 1984-02-21 | Chugai Denki Kogyo Kabushiki Kaisha | Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy |
US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
EG17619A (en) | 1984-10-09 | 1991-03-30 | Lilly Co Eli | An improved process for the production of a-21978 c derivatives |
CA1319886C (en) | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
EP0294990A3 (en) | 1987-06-10 | 1990-05-09 | Eli Lilly And Company | Chromatographic purification process |
CA1315229C (en) | 1987-06-10 | 1993-03-30 | Patrick J. Baker | Chromatographic purification process |
US4874843A (en) * | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
US5271935A (en) | 1988-02-05 | 1993-12-21 | Hoechst Aktiengesellschaft | Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical |
NZ232763A (en) | 1989-03-06 | 1991-09-25 | Lilly Co Eli | Parenteral formulation comprising daptomycin with a buffer to maintain ph between 6.0 and 8.0 |
DE69031730T2 (de) | 1990-01-26 | 1998-04-23 | Hoechst Ag | Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament |
JPH04224197A (ja) | 1990-12-26 | 1992-08-13 | Fujitsu Ltd | 生体高分子結晶化方法および装置 |
US5336756A (en) | 1991-05-01 | 1994-08-09 | Merck & Co., Inc. | Process for crystalline cyclic lipopeptides |
TW213468B (el) | 1991-06-29 | 1993-09-21 | Hoechst Ag | |
JP2948708B2 (ja) | 1991-11-27 | 1999-09-13 | ニューヨーク・ブラッド・センター・インコーポレーテッド | フィブロネクチン含有点眼液 |
ATE167871T1 (de) | 1992-04-20 | 1998-07-15 | Abbott Lab | Verfahren zur herstellung von vancomycin |
TW455591B (en) | 1993-06-08 | 2001-09-21 | Hoechst Ag | Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof |
DE4411025A1 (de) | 1994-03-30 | 1995-10-05 | Hoechst Ag | Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5952300A (en) | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
US5955509A (en) | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
JPH10212241A (ja) | 1996-05-27 | 1998-08-11 | Sumitomo Pharmaceut Co Ltd | Bdnfを安定に含有する製剤 |
FR2771640B1 (fr) | 1997-12-03 | 2000-02-11 | Inst Nat Sante Rech Med | Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques |
AU5528198A (en) | 1997-12-03 | 1999-06-16 | Immune Response Corporation, The | Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides |
FR2774687B1 (fr) | 1998-02-06 | 2002-03-22 | Inst Nat Sante Rech Med | Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques |
DE19807972A1 (de) | 1998-02-25 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung |
BR9914051A (pt) | 1998-09-25 | 2001-06-19 | Cubist Pharm Inc | Métodos para administração de antibióticos |
US7129274B1 (en) | 1999-11-05 | 2006-10-31 | Emisphere Technologies Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
US7279597B1 (en) | 1999-11-05 | 2007-10-09 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
US7408025B2 (en) | 1999-12-15 | 2008-08-05 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
AU6701101A (en) * | 2000-06-21 | 2002-01-02 | Cubist Pharm Inc | Compositions and methods to improve the oral absorption of antimicrobial agents |
US6716962B2 (en) | 2000-07-17 | 2004-04-06 | Micrologix Biotech Inc. | Extractive purification of lipopeptide antibiotics |
US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
IL156394A0 (en) | 2000-12-18 | 2004-01-04 | Cubist Pharm Inc | Methods for preparing purified lipopeptides |
WO2002059145A1 (en) | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
JP3932272B2 (ja) * | 2001-06-28 | 2007-06-20 | 明治乳業株式会社 | 多重t細胞エピトープポリペプチドの酢酸塩組成物 |
ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
KR20040032891A (ko) | 2001-08-06 | 2004-04-17 | 큐비스트 파마슈티컬즈 인코포레이티드 | 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및방법 |
WO2003059964A2 (fr) | 2002-01-17 | 2003-07-24 | Atofina | Polymeres supramoleculaires |
AU2003265264A1 (en) | 2002-07-09 | 2004-01-23 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
JP2005060377A (ja) * | 2003-07-28 | 2005-03-10 | Yamanouchi Pharmaceut Co Ltd | インターロイキン−11含有凍結乾燥製剤 |
US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
CN1616083A (zh) * | 2004-09-01 | 2005-05-18 | 魏雪纹 | 注射用达托霉素冻干制剂及制备方法 |
US7960337B2 (en) * | 2005-02-14 | 2011-06-14 | Venues Remedies Limited | Parenteral combination therapy for infective conditions with drug resistant bacterium |
WO2006130629A2 (en) | 2005-05-31 | 2006-12-07 | Cubist Pharmaceuticals, Inc. | Daptomycin for the treatment of biofilm and catheter salvage |
AU2006339311A1 (en) | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
SI2049142T2 (sl) * | 2006-07-26 | 2016-04-29 | Sandoz Ag | Formulacije kaspofungina |
EP2084519B1 (en) | 2006-10-10 | 2012-08-01 | Los Alamos National Security, LLC | X-ray fluorescence analysis method |
DE102007004968B4 (de) * | 2007-01-26 | 2011-03-10 | Heraeus Kulzer Gmbh | Revisions-Polymethylmethacrylat-Knochenzement |
WO2008102452A1 (ja) | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Hgf製剤 |
JP2010530846A (ja) * | 2007-06-01 | 2010-09-16 | アコロジックス インコーポレイティッド | 高温で安定なペプチド製剤 |
CA2692053A1 (en) | 2007-06-26 | 2008-12-31 | Merck Sharp & Dohme Corp. | Lyophilized anti-fungal composition |
JP5350388B2 (ja) * | 2007-10-25 | 2013-11-27 | ノバルティス アーゲー | 単位用量薬物パッケージの粉体調整 |
WO2009144739A1 (en) | 2008-05-26 | 2009-12-03 | Biocon Limited | Amorphous daptomycin and a method of purification thereof |
US8901072B2 (en) | 2009-08-12 | 2014-12-02 | The Medicines Company | Glycopeptide and lipoglycopeptide antibiotics with improved solubility |
US8431539B2 (en) | 2009-09-17 | 2013-04-30 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
CA2774094A1 (en) | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
US8835382B2 (en) | 2009-11-23 | 2014-09-16 | Cubist Pharmaceuticals, Inc. | Lipopeptide compositions and related methods |
WO2012061360A2 (en) | 2010-11-01 | 2012-05-10 | Rib-X Pharmaceuticals, Inc. | Pharmaceutical compositions |
AU2011348085B2 (en) | 2010-12-23 | 2016-12-08 | Alkermes Pharma Ireland Limited | Multi- API loading prodrugs |
WO2012112319A1 (en) | 2011-02-04 | 2012-08-23 | Aegis Therapeutics, Llc | Orally bioavailable peptide drug compositions and methods thereof |
-
2010
- 2010-11-23 US US13/511,246 patent/US8835382B2/en active Active
- 2010-11-23 TW TW105116907A patent/TWI606838B/zh active
- 2010-11-23 CN CN201810651754.1A patent/CN108785654A/zh active Pending
- 2010-11-23 AU AU2010321531A patent/AU2010321531C1/en active Active
- 2010-11-23 SG SG10201407724YA patent/SG10201407724YA/en unknown
- 2010-11-23 FI FIEP10832379.1T patent/FI2504353T4/fi active
- 2010-11-23 TW TW099140485A patent/TWI548414B/zh active
- 2010-11-23 DK DK10832379.1T patent/DK2504353T4/da active
- 2010-11-23 PE PE2012000703A patent/PE20121517A1/es active IP Right Grant
- 2010-11-23 TR TR2018/12823T patent/TR201812823T4/tr unknown
- 2010-11-23 CN CN201410208415.8A patent/CN104056250A/zh active Pending
- 2010-11-23 CN CN201080062122.3A patent/CN102712677B/zh active Active
- 2010-11-23 HU HUE10832379A patent/HUE039967T2/hu unknown
- 2010-11-23 WO PCT/US2010/057910 patent/WO2011063419A2/en active Application Filing
- 2010-11-23 HR HRP20181380TT patent/HRP20181380T4/hr unknown
- 2010-11-23 BR BR112012012406-4A patent/BR112012012406B1/pt active IP Right Grant
- 2010-11-23 AR ARP100104318 patent/AR079127A1/es not_active Application Discontinuation
- 2010-11-23 RU RU2012126076A patent/RU2607526C2/ru active
- 2010-11-23 JP JP2012540161A patent/JP6041673B2/ja active Active
- 2010-11-23 CA CA2781666A patent/CA2781666C/en active Active
- 2010-11-23 PT PT10832379T patent/PT2504353T/pt unknown
- 2010-11-23 RS RS20180974A patent/RS57566B2/sr unknown
- 2010-11-23 ES ES10832379T patent/ES2686331T5/es active Active
- 2010-11-23 SI SI201031736T patent/SI2504353T2/sl unknown
- 2010-11-23 EP EP10832379.1A patent/EP2504353B2/en active Active
- 2010-11-23 PE PE2015002039A patent/PE20151717A1/es unknown
- 2010-11-23 PL PL10832379.1T patent/PL2504353T5/pl unknown
- 2010-11-23 LT LTEP10832379.1T patent/LT2504353T/lt unknown
- 2010-11-23 EP EP18181723.0A patent/EP3417849A1/en active Pending
- 2010-11-23 MX MX2012005993A patent/MX2012005993A/es unknown
- 2010-11-23 NZ NZ600118A patent/NZ600118A/en unknown
-
2012
- 2012-05-18 DO DO2012000140A patent/DOP2012000140A/es unknown
- 2012-05-20 IL IL219891A patent/IL219891B/en not_active IP Right Cessation
- 2012-05-22 CR CR20120271A patent/CR20120271A/es unknown
- 2012-05-23 CL CL2012001336A patent/CL2012001336A1/es unknown
- 2012-05-31 EC ECSP12011939 patent/ECSP12011939A/es unknown
- 2012-06-08 CO CO12097444A patent/CO6541585A2/es unknown
-
2013
- 2013-12-04 US US14/096,346 patent/US9138456B2/en active Active
-
2015
- 2015-08-12 US US14/824,272 patent/US9662397B2/en active Active
- 2015-08-27 CL CL2015002412A patent/CL2015002412A1/es unknown
-
2016
- 2016-03-02 JP JP2016039505A patent/JP6088681B2/ja active Active
-
2017
- 2017-02-03 JP JP2017018290A patent/JP6239167B2/ja active Active
-
2018
- 2018-09-04 CY CY181100923T patent/CY1120854T1/el unknown
-
2021
- 2021-10-19 AR ARP210102879A patent/AR123846A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120854T1 (el) | Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι | |
CY1119276T1 (el) | Πολυπεπτιδια χλωροτοξινης και συζευγματα και χρησεις αυτων | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
CY1119979T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν τοξοειδη α και β toy clostridium difficile | |
CY1123217T1 (el) | Παγιδες gdf | |
CY1119974T1 (el) | Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης | |
CY1124924T1 (el) | Φαρμακευτικη συνθεση καρβετοκινης | |
CY1120638T1 (el) | Αναστολεις τυροσινικης κινασης πυριμιδινυλιου | |
EA202090868A1 (ru) | Составы | |
CY1117650T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
CY1121419T1 (el) | Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης | |
CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
UA104459C2 (uk) | Антитіла проти fgfr3 і способи їх застосування | |
EA201791383A1 (ru) | Наноносители, имеющие компоненты с различными скоростями высвобождения | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
UA112281C2 (uk) | Стабільні інсектицидні композиції і способи їх отримання | |
ECSP13012784A (es) | Anticuerpos anti-mesotelina e inmunoconjugados | |
CO7121325A2 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
CY1113713T1 (el) | Ανοσοκατασταλτικα πολυπεπτιδια και νουκλεϊκα οξεα | |
CR20160418A (es) | Nuevos compuestos biciclicos de 7 eslabones | |
MX346950B (es) | Reovirus que tienen secuencias modificadas. | |
EA201100268A1 (ru) | Вакцина | |
EP2569330A4 (en) | CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF | |
MX2009004862A (es) | Estabilizacion de vacunas por liofilizacion. | |
CY1118710T1 (el) | Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης |